U.S. Diabetes Pipeline Outlook

Table of Contents

1 EXECUTIVE SUMMARY

• Executive Summary
  • Introduction

2 MARKET INTRODUCTION

• Research Scope and Methodology
  • Scope and Segmentation
  • Research Methodology
• Diabetes Overview
  • Introduction
  • Types of Diabetes
  • Prevalence
  • Incidence
  • Current Treatment
• Pipeline Competitive Analysis
  • Introduction
  • Key Pipeline Companies
  • Areas of Opportunity

3 GLP-1 AGONISTS

• Introduction
  • GLP-1 Agonist Dynamics
• GLP-1 Agonists Pipeline Analysis
  • Byetta - Amylin & Eli Lilly
  • GLP-1 Agonist Pipeline

4 PULMONARY INSULIN

• Introduction
  • Pulmonary Insulin Dynamics
• Pulmonary Insulin Analysis
  • Exubera - Pfizer & Nektar
  • Pulmonary Insulin Pipeline

5 DPP-IV INHIBITORS

• Introduction
  • DPP-IV Dynamics
• DPP-IV Pipeline Analysis
  • Pipeline Analysis

6 PPAR MODULATORS

• Introduction
  • PPAR Dynamics
• PPAR Pipeline Analysis
  • PPAR Pipeline
  • Discontinued PPAR Modulators

7 OTHER PIPELINE EFFORTS

• Introduction
  • Other Development Efforts
• Pipeline Overviews
  • Other Insulin Pipeline
  • Other OAD Pipeline
  • Other IAD Pipeline

8 APPENDIX

• Decision Support Databases
  • Incidence of Diabetes
  • Prevalence of Diabetes
  • Diabetes Prevalence as a Percentage of Total Population
  • Diabetes Foot Ulcer Prevalence as a Percentage of Total Population
  • Total Population